Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-16 5:11 pm Purchase |
2025-04-09 | 13G | Larimar Therapeutics, Inc. LRMR |
Opaleye Management Inc. | 3,952,409 6.170% |
2,392,409 (+153.36%) |
Filing History |
| 2025-02-14 06:46 am Sale |
2024-12-31 | 13G | Ocular Therapeutix, Inc. OCUL |
Opaleye Management Inc. | 4,342,500 2.760% |
-1,727,500 (-28.46%) |
Filing History |
| 2025-02-14 06:42 am Purchase |
2024-12-31 | 13G | iBio, Inc. IBIO |
Opaleye Management Inc. | 750,000 7.600% |
100,000 (+15.38%) |
Filing History |
| 2025-02-14 06:31 am Purchase |
2024-12-31 | 13G | Protara Therapeutics, Inc. TARA |
Opaleye Management Inc. | 1,825,000 5.320% |
143,846 (+8.56%) |
Filing History |
| 2025-02-14 06:27 am Sale |
2024-12-31 | 13G | Context Therapeutics Inc. CNTX |
Opaleye Management Inc. | 0 0.000% |
-820,000 (Position Closed) |
Filing History |
| 2024-11-18 06:01 am Purchase |
2024-09-30 | 13G | Protara Therapeutics, Inc. TARA |
Opaleye Management Inc. | 1,681,154 8.150% |
1,681,154 (New Position) |
Filing History |
| 2024-10-22 7:44 pm Purchase |
2024-10-18 | 13G | SANUWAVE Health, Inc. SNWV |
Opaleye Management Inc. | 944,132 11.060% |
944,132 (New Position) |
Filing History |
| 2024-09-18 4:50 pm Purchase |
2024-09-17 | 13G | Codexis, Inc. CDXS |
Opaleye Management Inc. | 7,524,000 10.610% |
3,984,000 (+112.54%) |
Filing History |
| 2024-09-12 4:05 pm Purchase |
2024-09-09 | 13G | Eton Pharmaceuticals, Inc. ETON |
Opaleye Management Inc. | 2,722,500 10.340% |
197,613 (+7.83%) |
Filing History |
| 2024-07-12 4:15 pm Purchase |
2024-07-03 | 13G | Codexis, Inc. CDXS |
Opaleye Management Inc. | 3,540,000 5.020% |
3,540,000 (New Position) |
Filing History |
| 2024-04-09 5:22 pm Unchanged |
2024-03-28 | 13G | iBio, Inc. IBIO |
Opaleye Management Inc. | 650,000 7.630% |
0 (Unchanged) |
Filing History |
| 2024-04-08 8:18 pm Purchase |
2024-03-28 | 13G | iBio, Inc. IBIO |
Opaleye Management Inc. | 650,000 7.630% |
650,000 (New Position) |
Filing History |
| 2024-02-14 7:48 pm Sale |
2023-12-31 | 13G | Ocular Therapeutix, Inc. OCUL |
Opaleye Management Inc. | 6,070,000 5.510% |
-5,000 (-0.08%) |
Filing History |
| 2024-02-14 4:05 pm Purchase |
2023-12-31 | 13G | SANUWAVE Health, Inc. SNWV |
Opaleye Management Inc. | 307,983 9.090% |
224,173 (+267.48%) |
Filing History |
| 2024-02-09 4:05 pm Sale |
2023-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
Opaleye Management Inc. | 0 0.000% |
-2,810,000 (Position Closed) |
Filing History |
| 2024-02-09 4:05 pm Purchase |
2023-12-31 | 13G | Harrow Health, Inc. HROW |
Opaleye Management Inc. | 3,820,000 10.880% |
45,000 (+1.19%) |
Filing History |
| 2024-02-09 4:05 pm Sale |
2023-12-31 | 13D | TRACON Pharmaceuticals, Inc. TCON |
Opaleye Management Inc. | 0 0.000% |
-125,919 (Position Closed) |
Filing History |
| 2024-02-09 4:05 pm Purchase |
2023-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON |
Opaleye Management Inc. | 2,524,887 9.840% |
354,887 (+16.35%) |
Filing History |
| 2024-01-05 4:05 pm Purchase |
2023-12-27 | 13G | Context Therapeutics Inc. CNTX |
Opaleye Management Inc. | 820,000 5.140% |
820,000 (New Position) |
Filing History |
| 2023-04-12 4:15 pm Purchase |
2022-03-30 | 13G | Jounce Therapeutics, Inc. JNCE |
Opaleye Management Inc. | 2,810,000 5.390% |
2,810,000 (New Position) |
Filing History |